头颈部癌患者对生存素的抗体反应及其临床意义
Antibody responses to survivin and their clinical significance in patients with head and neck cancer.
作者信息
Eto Mayumi, Kodama Satoru, Uemura Naoki, Suzuki Masashi
机构信息
Department of Otolaryngology, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hazama-machi, Yufu, Oita 879-5593, Japan.
出版信息
Head Neck. 2007 Dec;29(12):1128-35. doi: 10.1002/hed.20652.
BACKGROUND
Survivin is highly expressed in cancer cells but shows little or no expression in normal tissues. Little is known about antibody responses to survivin in patients with head and neck cancer.
METHODS
Anti-survivin antibody responses in patients with head and neck cancer were investigated by enzyme-linked immunosorbent assay. Anti-p53 antibody and squamous cell carcinoma antigen were also examined.
RESULTS
Sera from 69 of 97 patients (71.1%) were positive for anti-survivin, with a cutoff value (absorbance; >0.673) with healthy control subjects. High levels of anti-survivin were detected in patients with advanced stage. Interestingly, levels of anti-survivin fell after curative treatment. In addition, 24 of 26 (92.3%) tested patients were positive for at least 1 of 3 markers.
CONCLUSIONS
These findings suggest that survivin may act as a major cancer antigen in head and neck cancer. Anti-survivin antibody responses may be a valuable marker in patients with head and neck cancer.
背景
生存素在癌细胞中高表达，但在正常组织中很少或不表达。关于头颈癌患者对生存素的抗体反应知之甚少。
方法
采用酶联免疫吸附试验研究头颈癌患者的抗生存素抗体反应。同时检测抗p53抗体和鳞状细胞癌抗原。
结果
97例患者中有69例（71.1%）血清抗生存素呈阳性，以健康对照者的临界值（吸光度；>0.673）判断。晚期患者检测到高水平的抗生存素。有趣的是，根治性治疗后抗生存素水平下降。此外，26例检测患者中有24例（92.3%）至少3种标志物中的1种呈阳性。
结论
这些发现表明生存素可能是头颈癌中的一种主要癌抗原。抗生存素抗体反应可能是头颈癌患者的一个有价值的标志物。
Zotero 插件